NewAmsterdam Pharma (NAMS) Competitors $33.01 +0.15 (+0.46%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$33.03 +0.02 (+0.06%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAMS vs. ASND, RDY, VTRS, ROIV, BBIO, QGEN, ELAN, MRNA, VRNA, and RVMDShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Qiagen (QGEN), Elanco Animal Health (ELAN), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Its Competitors Ascendis Pharma A/S Dr. Reddy's Laboratories Viatris Roivant Sciences BridgeBio Pharma Qiagen Elanco Animal Health Moderna Verona Pharma PLC American Depositary Share Revolution Medicines Ascendis Pharma A/S (NASDAQ:ASND) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment. Which has higher earnings & valuation, ASND or NAMS? NewAmsterdam Pharma has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$393.54M33.67-$409.12M-$5.16-41.62NewAmsterdam Pharma$45.56M81.60-$241.60M-$1.62-20.38 Which has more volatility and risk, ASND or NAMS? Ascendis Pharma A/S has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Does the media refer more to ASND or NAMS? In the previous week, Ascendis Pharma A/S had 6 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 4 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.87 beat Ascendis Pharma A/S's score of 0.64 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ASND or NAMS more profitable? Ascendis Pharma A/S has a net margin of -54.94% compared to NewAmsterdam Pharma's net margin of -259.07%. Ascendis Pharma A/S's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-54.94% N/A -24.31% NewAmsterdam Pharma -259.07%-27.27%-25.00% Do analysts rate ASND or NAMS? Ascendis Pharma A/S currently has a consensus target price of $244.64, indicating a potential upside of 13.91%. NewAmsterdam Pharma has a consensus target price of $42.00, indicating a potential upside of 27.23%. Given NewAmsterdam Pharma's higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 1 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.88NewAmsterdam Pharma 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Do institutionals & insiders have more ownership in ASND or NAMS? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryAscendis Pharma A/S beats NewAmsterdam Pharma on 9 of the 16 factors compared between the two stocks. Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.70B$2.65B$6.15B$10.64BDividend YieldN/A56.69%5.66%4.69%P/E Ratio-20.3823.7585.9927.64Price / Sales81.60807.24628.97141.97Price / CashN/A177.3038.3262.20Price / Book4.035.6412.956.79Net Income-$241.60M$32.78M$3.30B$275.88M7 Day Performance7.63%5.19%3.69%1.84%1 Month Performance22.71%14.48%10.68%8.84%1 Year Performance87.34%3.73%83.35%36.10% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma3.1245 of 5 stars$33.01+0.5%$42.00+27.2%+86.7%$3.70B$45.56M-20.384Analyst ForecastASNDAscendis Pharma A/S3.0121 of 5 stars$195.48+2.0%$244.36+25.0%+66.1%$11.95B$393.54M-37.601,017News CoveragePositive NewsAnalyst ForecastRDYDr. Reddy's Laboratories3.0515 of 5 stars$13.90-2.2%$16.95+21.9%-10.1%$11.60B$334.26B21.0527,811Analyst ForecastVTRSViatris1.8207 of 5 stars$9.67+0.5%$10.40+7.6%-12.4%$11.27B$14.74B-3.3332,000Positive NewsAnalyst ForecastROIVRoivant Sciences3.4439 of 5 stars$15.15+0.3%$19.94+31.6%+40.1%$10.27B$23.23M-21.49860Trending NewsAnalyst ForecastInsider TradeBBIOBridgeBio Pharma4.2026 of 5 stars$52.25+0.6%$63.94+22.4%+134.3%$9.98B$221.90M-12.76400Analyst ForecastQGENQiagen4.4153 of 5 stars$43.95+0.0%$49.69+13.1%+8.7%$9.76B$1.98B25.955,765Analyst ForecastELANElanco Animal Health2.6234 of 5 stars$19.56-0.3%$18.33-6.2%+37.4%$9.75B$4.44B22.829,000Analyst UpgradeMRNAModerna4.3114 of 5 stars$24.86-1.8%$41.81+68.2%-53.2%$9.67B$3.24B-3.305,800Analyst ForecastVRNAVerona Pharma PLC American Depositary Share1.8705 of 5 stars$106.69+0.1%$109.00+2.2%N/A$9.19B$42.28M-107.7530Positive NewsAnalyst ForecastRVMDRevolution Medicines4.1563 of 5 stars$46.02-0.1%$74.64+62.2%-3.8%$8.57B$11.58M-10.19250Analyst Forecast Related Companies and Tools Related Companies Ascendis Pharma A/S Alternatives Dr. Reddy's Laboratories Alternatives Viatris Alternatives Roivant Sciences Alternatives BridgeBio Pharma Alternatives Qiagen Alternatives Elanco Animal Health Alternatives Moderna Alternatives Verona Pharma PLC American Depositary Share Alternatives Revolution Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAMS) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredToo busy for AI trading?Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | SponsoredTesla’s $30 trillion pivotElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Company N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
